OBJECTIVES: To determine the phylogenetic group distribution and prevalence of three major globally disseminated clonal groups [clonal group A (CGA) and O15:K52:H1, associated with phylogenetic group D, and sequence type ST131, associated with phylogenetic group B2] among fluoroquinolone-resistant extra-intestinal Escherichia coli isolates from humans and companion animals in Australia. METHODS: Clinical extra-intestinal fluoroquinolone-resistant E. coli isolates were obtained from humans (n = 582) and companion animals (n = 125), on Australia's east coast (October 2007-October 2009). Isolates were tested for susceptibility to seven antimicrobial agents, and for phylogenetic group, O type and clonal-group-specific single nucleotide polymorphisms by PCR. RESULTS: The fluoroquinolone-resistant isolates were typically resistant to multiple agents (median of four). Analysis revealed that clonal group ST131 accounted for a large subset of the human isolates (202/585, 35%), but for a much smaller proportion of the companion animal isolates (9/125, 7.2%; P <or= 0.001). In contrast, CGA and O15:K52:H1 were uncommon among both human (7.2%) and companion animal (0.8%) isolates. CONCLUSIONS: In Australia, a large proportion (42%) of recent fluoroquinolone-resistant extra-intestinal E. coli isolates from humans are represented by three major globally disseminated clonal groups, predominantly ST131, which by contrast is comparatively rare among fluoroquinolone-resistant E. coli from companion animals. In conjunction with Australia's ban on fluoroquinolone use in livestock, these results argue against a major domestic food animal or companion animal source for fluoroquinolone-resistant extra-intestinal E. coli among humans in Australia. However, both humans and companion animals are involved in the intercontinental emergence and dissemination of ST131.
OBJECTIVES: To determine the phylogenetic group distribution and prevalence of three major globally disseminated clonal groups [clonal group A (CGA) and O15:K52:H1, associated with phylogenetic group D, and sequence type ST131, associated with phylogenetic group B2] among fluoroquinolone-resistant extra-intestinal Escherichia coli isolates from humans and companion animals in Australia. METHODS: Clinical extra-intestinal fluoroquinolone-resistant E. coli isolates were obtained from humans (n = 582) and companion animals (n = 125), on Australia's east coast (October 2007-October 2009). Isolates were tested for susceptibility to seven antimicrobial agents, and for phylogenetic group, O type and clonal-group-specific single nucleotide polymorphisms by PCR. RESULTS: The fluoroquinolone-resistant isolates were typically resistant to multiple agents (median of four). Analysis revealed that clonal group ST131 accounted for a large subset of the human isolates (202/585, 35%), but for a much smaller proportion of the companion animal isolates (9/125, 7.2%; P <or= 0.001). In contrast, CGA and O15:K52:H1 were uncommon among both human (7.2%) and companion animal (0.8%) isolates. CONCLUSIONS: In Australia, a large proportion (42%) of recent fluoroquinolone-resistant extra-intestinal E. coli isolates from humans are represented by three major globally disseminated clonal groups, predominantly ST131, which by contrast is comparatively rare among fluoroquinolone-resistant E. coli from companion animals. In conjunction with Australia's ban on fluoroquinolone use in livestock, these results argue against a major domestic food animal or companion animal source for fluoroquinolone-resistant extra-intestinal E. coli among humans in Australia. However, both humans and companion animals are involved in the intercontinental emergence and dissemination of ST131.
Authors: Thomas J Hannan; Makrina Totsika; Kylie J Mansfield; Kate H Moore; Mark A Schembri; Scott J Hultgren Journal: FEMS Microbiol Rev Date: 2012-05 Impact factor: 16.408
Authors: Sam Abraham; Toni A Chapman; Ren Zhang; James Chin; Amanda N Mabbett; Makrina Totsika; Mark A Schembri Journal: J Clin Microbiol Date: 2011-12-21 Impact factor: 5.948
Authors: Joanne L Platell; Rowland N Cobbold; James R Johnson; Anke Heisig; Peter Heisig; Connie Clabots; Michael A Kuskowski; Darren J Trott Journal: Antimicrob Agents Chemother Date: 2011-06-06 Impact factor: 5.191
Authors: Joanne L Platell; Darren J Trott; James R Johnson; Peter Heisig; Anke Heisig; Connie R Clabots; Brian Johnston; Rowland N Cobbold Journal: Antimicrob Agents Chemother Date: 2012-04-23 Impact factor: 5.191
Authors: Tessa E LeCuyer; Barbara A Byrne; Joshua B Daniels; Dubraska V Diaz-Campos; G Kenitra Hammac; Claire B Miller; Thomas E Besser; Margaret A Davis Journal: J Clin Microbiol Date: 2018-08-27 Impact factor: 5.948
Authors: Allen C Cheng; John Turnidge; Peter Collignon; David Looke; Mary Barton; Thomas Gottlieb Journal: Emerg Infect Dis Date: 2012-09 Impact factor: 6.883
Authors: Makrina Totsika; Scott A Beatson; Sohinee Sarkar; Minh-Duy Phan; Nicola K Petty; Nathan Bachmann; Marek Szubert; Hanna E Sidjabat; David L Paterson; Mathew Upton; Mark A Schembri Journal: PLoS One Date: 2011-10-28 Impact factor: 3.240